New 2-, 4- and 5-nitroimidazole analogues were synthesised using the following methods: (i) SRN1 free radical reaction between nitroimidazole anion and halonitro substrates; (ii) oxidative addition of the anion of 2-nitropropane to nitroimidazole anions. N-1-alkyl derivatives of imidazole, benzimidazole, 5-nitrobenzimidazole, 5- and 6-nitroindazole were similarly prepared. These compounds showed antimicrobial activity; anaerobes were more sensitive than aerobes.

No description available.

Ce travail s’inscrit dans la recherche de nouveaux 5-nitroimidazoles fonctionnalisés à visée thérapeutique. L’étude de la réactivité du 4-bromo-1,2-diméthyl-5-nitro-1H-imidazole vis-à-vis des réactions de couplages de Suzuki, Sonogashira et Stille a permis la synthèse de nouveaux 5-nitroimidazoles substitués en position 4. Par ailleurs, un couplage de Suzuki régiosélectif a pu être mis au point sur le 2,4-dibromo-1-méthyl-5-nitro-1H-imidazole permettant l’accès en une seule étape à des composés substitués à la fois en positions 2 et 4. Parmi les composés synthétisés via ces couplages pallado-catalysés, les dérivés chlorométhylés conjugués avec le groupement nitro ont été utilisés en tant que substrats pour l’étude de réactions par transfert monoélectronique (SRN1, TDAE). Ainsi, dans une seconde partie, nous décrivons la réaction entre le 4-(3-chloroprop-1-ynyl)-1,2-diméthyl-5-nitro-1H-imidazole et plusieurs anions nitronates dans des conditions de SRN1. Cette réactivité a pu être étendue au 2,4-bis(3-chloroprop-1-ynyl)-1-méthyl-5-nitro-1H-imidazole permettant la réalisation d’une bis-SRN1. La méthodologie TDAE a été mise en œuvre sur le 4-(3-chloroprop-1-ynyl)-1,2-diméthyl-5-nitro-1H-imidazole, avec de faibles rendements observés, contrairement à ceux obtenus avec le (E)-4-[4- (chlorométhyl)styryl]-1,2-diméthyl-5-nitro-1H-imidazole sur lequel plusieurs types d’électrophile ont pu être additionnés. Enfin, le pouvoir mutagène, ainsi que le potentiel de réduction des 5-nitroimidazoles synthétisés ont été déterminés. L’évaluation anti-infectieuse est actuellement en cours sur des souches de Giardia lamblia et sur une grande variété de bactéries anaérobies strictes. / This work focuses on the synthesis of novel functionalized 5-nitroimidazoles possessing therapeutic activities. New 4-substituted-5-nitroimidazoles were obtained using Suzuki, Stille or Sonogashira cross-coupling using the 4-bromo-1,2 dimethyl-5-nitro-1H-imidazole. Moreover, access to functionalized products at both 2 and 4 positions of imidazole ring was developed thanks to a regioselective Suzuki cross-coupling on the 2,4-dibromo-1-methyl-5-nitro-1H-imidazole. Among cross-coupling products, those possessing chloromethyle substituent conjugated with the nitro group, were employed as starting material in the single electron transfer reaction (SRN1, TDAE) studies. Therefore, in a second part, we described the reaction between the 4-(3-chloroprop-1-ynyl)-1,2-dimethyl-5-nitro-1H-imidazole and several nitronate anions in SRN1 conditions. This reactivity was applied to the 2,4-bis(3-chloroprop-1-ynyl)-1-méthyl-5-nitro-1H-imidazole allowing the formation of bis-SRN1 products. TDAE methodology was implemented on the 4-(3-chloroprop-1-ynyl)-1,2-dimethyl-5-nitro-1H-imidazole, however poor yields were observed. TDAE strategy on the (E)-4-[4-(chlorométhyl)styryl]-1,2-diméthyl-5-nitro-1H-imidazole were more successful, addition products with different electrophilic species were obtained. Finally, mutagenic power and potential of reduction of synthesized 5-nitroimidazole were assayed. The anti-infective properties of these novel 5-nitroimidazole are currently under investigation.

Evolution of strategies for biodegradation of synthetic organic pollutants relies on recruitment of genes from catabolic pathways for natural compounds. Investigation of metabolic diversity in nature can provide insight into biochemical strategies that could be recruited for bioremediation of pollutants. As part of a search for novel metabolic diversity we isolated soil bacteria able to degrade 2-nitroimidazole (2NI) and 5-nitroanthranilic acid (5NAA), and determined the biochemistry and molecular biology of their biodegradation pathways. 2NI and its analogs are increasingly used as prodrugs for the treatment of both tuberculosis and cancer. The biodegradation of 2NI by a soil Mycobacterium sp. is initiated by an unusual hydrolytic denitration. The reaction is catalyzed by a novel nitrohydrolase with a divergent sequence and represents the discovery of a previously unreported drug resistance mechanism in soil prior to its identification in clinical situations. 5NAA is the starting material for various nitroaromatic compounds and dyes. The biodegradation pathway of 5NAA is initiated by an unusual hydrolytic deamination. The corresponding gene is very distantly related to biochemically characterized genes in the NCBI database. The nitro group of 5NAA is eliminated as nitrite during the spontaneous formation of lactones from a ring fission product, a previously unreported mechanism. Degradation pathways of 5NAA and 2NI serve as precedents for those of nitroaniline and nitroimidazole pollutants. The work supports the hypothesis that the study of the metabolism of natural organic compounds selected on the basis of unusual structural features and ecological roles can reveal new metabolic diversity.

Ce travail est consacré à la synthèse et à la fonctionnalisation d’hétérocycles d’intérêt biologique par méthodologie TDAE. Dans une première partie, nous avons développé la réactivité initiée par le TDAE de nouveaux électrophiles en série nitrobenzylique. L’emploi des aldéhydes-a,ß-éthyléniques et des aldéhydes hétérocycliques nous a permis d’identifier le type d’addition nucléophile de l’anion du chlorure de p-nitrobenzyle (classique ou Michael). La réaction sur une double liaison carbone-azote est possible grâce à l’emploi des iminiums quaternaires. Nous avons présenté le premier exemple de double réactivité initiée par le TDAE en faisant appel aux dialdéhydes aromatiques. Une méthodologie courte et originale nous a permis de synthétiser des quinoléines en deux étapes par association de la stratégie TDAE (avec les dicétones comme électrophiles) et de la réaction de réduction-cyclisation. Dans une deuxième partie, nous avons appliqué la méthodologie TDAE pour la découverte de composés d’intérêt pharmacologique. Après avoir synthétisé le 6-chlorométhyl-5-nitroimidazo[2,1-b]thiazole, nous avons étudié sa réactivité initiée par le TDAE avec divers a-cétoesters. Les produits obtenus ont été testés comme antibactériens et antifongiques et ont révélé une spécificité d’action sur Candida tropicalis. Dans une troisième partie, nous avons entrepris la synthèse du 4-[4-(chlorométhyl)phényl]-1,2-diméthyl-5-nitro-1H-imidazole. La réactivité initiée par le TDAE de ce substrat avec différents électrophiles (aldéhydes, a-cétoesters, dicétones) a conduit à de nouveaux alcools potentiellement actifs comme antiparasitaires notamment sur Trichomonas vaginalis. / This work is focused on the synthesis and the functionalization of potentially bioactive heterocyclic compounds by TDAE methodology. In the first part, we have developed the TDAE reaction with new electrophiles in nitrobenzylic series. By using ethylenic and heterocyclic aldehydes, we have identified the kind of nucleophilic addition (classic or Michael). The reaction on a carbon-nitrogen double bond is possible with the utilization of quaternary iminiums. We have presented the first example of double TDAE-initiated reactivity with aromatic dialdehydes. A short and original methodology allows us to synthesize quinolines in a two steps TDAE-initiated reaction (using diketones as electrophiles) and reduction-cyclization reaction. In the second part, we have applied the TDAE methodology in order to discover pharmacological compounds. After synthesizing the 6-chloromethyl-5-nitroimidazo[2,1-b]thiazole, we have studied its reactivity with different a-ketoesters. All the products were tested as antibacterial and antifungal compounds; they show a specific activity against Candida tropicalis. In the third part, we synthesized the 4-[4-(chloromethyl)phenyl]-1,2-dimethyl-5-nitro-1H-imidazole. The TDAE-initiated reactivity of this substrate with different electrophiles (aldehydes, a-ketoesters, diketones) furnish new potentially bioactive alcohols as antiparasitic agents especially against Trichomonas vaginalis.

Ce travail de thèse est consacré à la synthèse et l’évaluation biologique de nouveaux nitromidazoles à potentialités anti-infectieuses. Dans les trois premiers chapitres, nous avons abordé les propriétés biologiques des 5-nitroimidazoles, et la synthèse de nouveaux composés fonctionnalisés en positions 2 et 4 dans le but d'améliorer l'activité sur les souches résistantes au métronidazole, le 5-nitroimidazole de référence, tout en contrôlant au mieux la mutagénicité. Nous avons développé une méthode de couplage régiosélectif de Suzuki-Miyaura en position 4 du 2,4-dibromo-1-méthyl-5-nitro-1H-imidazole, suivi d’un deuxième couplage de Suzuki-Miyaura ou de Sonogashira par méthodologie « one-pot » séquentielle en position 2. Cette méthodologie nous a permis d’obtenir 30 nouveaux composés qui ont été testés pour leur propriétés antibactériennes et antiparasitaires. Une dizaine de composés ont été synthétisés par méthodologie TDAE sur le 4-[4-(chlorométhyl)phényl]-1,2-diméthyl-5-nitro-1H-imidazole. Dans le dernier chapitre, nous avons initié un travail de pharmacomodulation en série imidazooxazole, motif bien connu pour ses propriétés antituberculeuses et antileishmaniennes. Nous avons présenté la synthèse et l’évaluation biologique de dérivés 5-nitroimidazooxazoles et 7-nitro-2,3-dihydroimidazo[5,1-b]oxazoles. La synthèse de dérivés 6-nitroimidazooxazoles fonctionnalisés en position 5 est en cours de développement et nous avons présenté quelques essais de CH-arylation sur le 2-méthyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole. / We have developed in this work the synthesis and the biological evaluation of novel nitromidazoles with anti-infectious potentialities. In the first three parts, we discussed the biological properties of 5-nitroimidazole scaffold, and the synthesis of new compounds functionalized at 2- and 4-position in order to improve the activity on metronidazole-resistant strains, while controlling mutagenicity. We developed a regioselective Suzuki-Miyaura cross- coupling reaction at 4-position of 2,4-dibromo-1-methyl-5-nitro-1H-imidazole, followed by a second Suzuki-Miyaura or Sonogashira cross-coupling reaction at 2-position by a "one-pot" sequential process. This methodology has enabled us to obtain 30 new products which were tested for their antibacterial and antiparasitic properties. Twelve compounds were synthesized by TDAE methodology on {4- [4- (chloromethyl) phenyl]} -1,2-dimethyl-5-nitro-1H-imidazole. In the last part, we initiated a work of pharmacomodulation in imidazooxazole series, scaffold well-known for its antituberculous and antileishmanial properties. We have described the synthesis and the biological evaluation of 6-functionalized 5-nitroimidazooxazole and 7-nitro-2,3-dihydroimidazo [5,1-b]oxazole derivatives. We have presented some CH-arylation assays on 2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole to obtain 5-functionalized 6-nitroimidazooxazole derivatives.

O tumor sob hipóxia apresenta resistência a terapia antitumoral convencional por diferentes mecanismos. O uso de métodos diagnósticos moleculares não invasivos, como imagem por PET, permite a identificação de tumores sob hipóxia e auxilia no delineamento da estratégia terapêutica mais adequada. Atualmente, diversas pesquisas têm demonstrado alternativas ao tratamento de tumores sob hipóxia, explorando características como, potencial redutor do tumor e inibição de mecanismos de adaptação celular para a sobrevivência sob essa condição. Assim, neste trabalho foi realizada a síntese e avaliação in vivo de novo derivado 2-nitroimidazol, contendo o grupo hidrofílico zwiteriônico amôniometil-trifluoroborato (AMBF3), 18F-AmBF3-bu-2NI, com potencial para geração de imagens de tumores sob hipóxia. O composto AmBF3-bu-2NI foi facilmente preparado em 4 etapas sintéticas. A marcação com 18F foi realizada via reação de troca isotópica 18F-19F e 18F-AmBF3-bu-2NI foi obtido em 14,8 ± 0,4% de rendimento radioquímico (n = 3) com decaimento corrigido, 24,5 ± 5,2 GBq/?mol de atividade específica e >99% de pureza radioquímica. Estudos de imagem e biodistribuição ex vivo em camundongos, portando tumores HT-29, demonstraram que 18F-AmBF3-bu-2NI possui rápido clearance do sangue, com excreção pelas vias hepatobiliar e renal. No entanto, o tumor não foi visualizado em imagens de PET até 3 h pós-injeção devido à baixa captação tumoral (0,54 ± 0,13 e 0,19 ± 0,04% AI/g em 1 e 3 h pós-injeção, respectivamente), devido à não difusão de 18F-AmBF3-bu-2NI através da membrana celular. Adicionalmente, compostos quinazolinicos com potencial aplicação em diagnóstico foram também sintetizados contendo unidades biorredutives, nitro-benzil e nitro-imidazol, além de grupo fluoroetil, inicialmente contendo 19F (frio), como padrão analítico para a síntese do radiotraçador. Entretanto, devido a formação de produtos voláteis durante a radiossíntese da unidade 2-[18F]fluoroetil 4-metilbenzenosulfonato (34*), para incorporação no anel quinazolínico, a obtenção do radiotraçador e os correspondentes estudos de biodistribuição e imagem não foram realizados. Em paralelo ao trabalho anterior, foi realizada a síntese de um conjunto de 12 compostos aminotriazolil-quinazolínicos com potencial atividade antitumoral, via reação de cicloadição CuAAC. Inicialmente todos derivados quinazolínicos obtidos no trabalho para aplicação no diagnóstico foram testados em uma série de linhagens de células tumorais sob condições de normóxia e hipóxia (MDA-MB-231, SKBR3, BT474, PC3, MKN45, U251, U87, MIA PaCa-2, Skmel37, e A549, na concentração de 10 ?M), empregando cisplatina como referência. Neste estudo, apenas os derivados contendo grupo nitro-benzil-triazólico 61 e 63, apresentaram cerca de 50% de inibição de células MKN45 em normóxia e 40% em células SKBR3 sob hipóxia, respectivamente. Na sequência, os 12 derivados aminotriazolil-quinazolínicos foram submetidos a avaliação da citotoxicidade in vitro sob as linhagens de células tumorais de mama (MDA-MB-231, SKBR3, BT474, na concentração de 30 ?M), empregado os controles positivos Erlotinib e ii Lapatinib. Apenas o derivado contendo a função ftalimida 9, não substituído nas posições C-6 e C-7 do anel quinazolínico, apresentou cerca de 60% de inibição de células SKBR3 em hipóxia. Paralelamente, os derivados aminotriazolil-quinazolínicos foram submetidos à avaliação de triagem da atividade inibitória frente as quinases HER2, EGFR e PERK, na concentração de 10 ?M. Todavia, não houve inibição significativa nas enzimas avaliadas na concentração testada. Novos ensaios estão em andamento a fim de determinar a capacidade dos compostos atuarem como inibidores do crescimento de outras linhagens de células tumorais. / Tumor hypoxia is resistant to conventional antitumor therapy by different mechanisms. The use of non-invasive molecular diagnostic methods, such as PET imaging, allows the identification of tumors under hypoxia and assists in designing the most appropriate therapeutic strategy. Currently, several researches have provided alternative treatments for tumors under hypoxia, exploring some specific properties, such as tumor reducing potential and inhibition of adaptive mechanisms required for cell survival under hypoxia. Thus in this work, it was performed the synthesis and in vivo evaluation of new 2-nitroimidazole derivative, containing the zwitterionic hydrophilic group, ammonium methyl- trifluoroborate (AMBF3), 18F-AmBF3-bu-2NI, with potential for tumor imaging in hypoxia. The compound AmBF3-bu-2NI was easily prepared in four steps. 18F labeling was conducted via 18F-19F isotope exchange reaction, and 18F-AmBF3-bu-2NI was obtained in 14.8 ± 0.4% (n = 3) decay-corrected radiochemical yield with 24.5 ± 5.2 GBq/?mol specific activity and > 99% radiochemical purity. Imaging and biodistribution ex vivo studies in HT-29 tumor-bearing mice showed that 18F-AmBF3-bu-2NI cleared quickly from blood, and was excreted via the hepatobiliary and renal pathways. However, tumor PET images were not visualized until 3 h post-injection due to low tumor uptake (0.54 ± 0.13 and 0.19 ± 0.04%ID/g at 1 h and 3 h post-injection, respectively) due to non-diffusion of 18F-AmBF3-bu-2NI through the cell membrane. Additionally, quinazolinic compounds with potential diagnostic application were also synthesized containing biorreductive units, nitrobenzyl and nitroimidazole, as well as a fluoroethyl group, initially containing 19F (cold), as an analytical standard for the synthesis of the radiotracer. However, due to the formation of volatile products during the radiosynthesis of the 2-[18F] fluoroethyl 4-methylbenzenesulfonate (34*) unit, for incorporation into the quinazoline ring, the radiotracer preparation and its corresponding biodistribution and imaging studies were not performed. Concomitantly to the previous work, the synthesis of a set of 12 aminotriazolyl-quinazoline compounds with potential antitumor activity was performed, via the CuAAC cycloaddition reaction. Initially, all quinazolinic derivatives obtained in the work for application in the diagnosis were tested in a range of tumor cell lines under normoxia and hypoxia conditions (MDA-MB-231, SKBR3, BT474, PC3, MKN45, U251, U87, MIA PaCa-2, Skmel37, and A549, at 10 ?M), using cisplatin as a reference. In this study, only the derivatives bearing the nitrobenzyltriazole group 61 and 63 showed about 50% inhibition of MKN45 cells in normoxia and 40% in SKBR3 cells under hypoxia, respectively. In the sequence, the 12 aminotriazolyl-quinazoline derivatives were submitted to in vitro cytotoxicity evaluation using breast tumor cell lines (MDA-MB-231, SKBR3, BT474, at 30 ?M), in the presence of the reference drugs Erlotinib and Lapatinib. Only the derivative containing the phthalimide function 9, unsubstituted at C-6 and C-7 positions of the quinazoline ring, displayed about 60% inhibition on SKBR3 cells under hypoxia. Concomitantly, the inhibitory iv activity of these aminotriazolyl-quinazoline derivatives were also subjected to a screening evaluation against the HER2, EGFR and PERK kinases, 10 ?M. However, there was no significant inhibition of these enzymes at the tested concentration. New assays are ongoing to determine the inhibitory activity under other tumor cell lines.

Submitted by Biblioteca da Faculdade de Farmácia (bff@ndc.uff.br) on 2018-01-17T14:43:51Z No. of bitstreams: 1 PATRÍCIA PEREIRA FARIAS.PDF: 3725473 bytes, checksum: 27a790c0c992ee9cf80615ba7199bc05 (MD5) / Made available in DSpace on 2018-01-17T14:43:51Z (GMT). No. of bitstreams: 1 PATRÍCIA PEREIRA FARIAS.PDF: 3725473 bytes, checksum: 27a790c0c992ee9cf80615ba7199bc05 (MD5) / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / As doenças parasitárias são um grave problema de saúde pública em diversos países e estão distribuídas, principalmente, em áreas endêmicas em países da África, Ásia, América Central e do Sul. Entre estas doenças estão a doença de Chagas e a doença do Sono, reconhecidas como negligenciadas. Há uma necessidade de tratamentos mais eficientes para essas doenças devido a toxicidade, baixa eficácia e segurança dos fármacos existentes, além da dificuldade de administração e evolução de resistência. O grupo de pesquisa da Dra. Núbia Boechat (Farmanguinhos/FIOCRUZ), vem realizando estudos com análogos nitroimidazólicos sintetizados considerando o megazol como protótipo, molécula ativa contra Trypanosoma cruzi, porém com efeitos mutagênicos e genotóxicos. Estes derivados apresentaram atividade contra o T. cruzi, com menor efeito genotóxico quando comparados com o megazol. Através deste trabalho, a relação estrutura-atividade dos derivados nitroimidazólicos (40a, 40b e 41a-41h) foi realizada e através dos descritores eletrônicos HOMO e LUMO, observou-se que grupos volumosos e com caráter retirador de elétrons do anel nitroimidazólico apresentam relação direta com a atividade. A avaliação do perfil toxicológico in silico confirmou que o composto 41a, mais ativo da série, não apresentou citotoxicidade em células sanguíneas humanas in vitro. O modelo da enzima nitrorredutase de T. cruzi, construído por modelagem comparativa, pode ser utilizado nos estudos de docagem molecular, os quais sugeriram que o tamanho da molécula, a possibilidade de interação com os resíduos His503 e Tyr545 e interações hidrofóbicas do tipo π-π com o cofator FMN podem contribuir para a atividade de derivados nitroimidazólicos no sítio ativo da enzima nitrorredutase. Através dos estudos de docagem molecular, sete novos derivados otimizados foram propostos (PR01 a PR07), dentre os quais o PR03, considerado como melhor ligante planejado, apresentou interações no sítio ativo similares às observadas para o protótipo 41a. Desta forma, os resultados obtidos neste trabalho podem ser úteis a novas pesquisas e podem contribuir para o desenvolvimento de novos protótipos contra o T. cruzi / Parasitic diseases are a major public health problem in many countries, and they are distributed primarily in endemic areas in Africa, Asia, Central and South America. Among them, there are Chagas disease and African trypanosomiasis, known as neglected. There is a need for better treatments for these diseases due to toxicity, low efficacy and safety of the existing drugs, besides the difficulty of administration and evolution of resistance. The research group of Dr. Núbia Boechat (Farmanguinhos/FIOCRUZ), has been conducting studies with nitroimidazole analogs synthesized through the prototype megazol (active molecule against trypanosoma, but with mutagenic and genotoxic effects). In this work, the structure activity relationship of the nitroimidazole derivatives (40a, 40b and 41a-41h) was performed and it was observed through the electronic descriptors HOMO and LUMO that groups with electron withdrawing character display relation with activity. In silico toxicological studies confirmed that the most active compound 41a did not show cytotoxicity in human blood cells in vitro. T. cruzi type I nitroreductase constructed by comparative modeling, can be used in molecular docking studies, which suggested that the size of the molecule, the possibility of interaction with the residues His503 and Tyr545, and hydrophobic interactions of the π- Π with the FMN cofactor may contribute to the activity of nitroimidazole derivatives in the active site of the nitroreductase. From molecular docking studies, seven new optimized derivatives were proposed (PR01 to PR07), among them PR03 was considered as the best planned molecule, it displayed similar active site interactions to those observed for prototype 41a. Thus, the results obtained in this work may be useful to new research and may contribute to the development of new prototypes against T. cruzi

L'objectif de ce travail consiste en la synthèse de nouveaux 5-nitroimidazoles fonctionnalisés à visée thérapeutique. Dans un premier temps, l'étude de la réactivité du 4-bromo-1,2-diméthyl-5-nitro-1H-imidazole vis-à-vis du couplage de Suzuki-Miyaura sous irradiation micro-ondes a permis la synthèse de nouveaux produits substitués en position 4 par différents groupements aryle ou styryle. Dans un second temps, la réactivité LD-SRN1 a été étudiée entre le 4-[4-(chlorométhyl)phényl]-1,2-diméthyl-5-nitro-1H-imidazole et différents nucléophiles centrés sur l'atome de carbone ou de soufre. Cette étude a révélé l'importance de la température dans l'activation de la réaction par transfert monoélectronique. De nouveaux dérivés substitués en position 4 par divers groupements sulfonyles ont ensuite été synthétisés, par réactions SN2 et SNAr entre des dérivés 5-nitroimidazolés et différents anions sulfinates. Cette synthèse a été suivie par la mise au point de tests biologiques sur Trichomonas vaginalis. L'activité trichomonacide a été évaluée sur certaines de ces molécules, à l'origine de relations structure-activité montrant l'influence de la position du groupement sulfonyle substituant le noyau 5-nitroimidazole. La dernière partie de ce travail décrit une réaction de O-arylation pallado-catalysée inattendue et originale, d'un dérivé fluoré en série nitro(o-nitrophényl)imidazole impliquant des acides arylboroniques dans les conditions opératoires de la réaction de Suzuki-Miyaura. / The aim of this work consists of the synthesis of new potentially bioactive functionalized 5-nitroimidazoles. Initially, the reactivity study of the 4-bromo-1,2-dimethyl-5-nitro-1H-imidazole under microwave-assisted Suzuki-Miyaura cross-coupling conditions gave new derivatives substituted by various aryl or styryl groups in 4-position. In a second step the 4-[4-(chloromethyl)phenyl]-1,2-dimethyl-5-nitro-1H-imidazole was prepared in order to study LD-SRN1 reactivity with different carbon and sulphur centered nucleophiles. This study pointed the role of the temperature for the electron transfer reactions. Then, new 4-position sulfonyl substituted derivatives were synthesized by SN2 and SNAr reactions between sulfinate anions and three substrates in 5-nitroimidazole series. This synthesis was followed by the development of biological assays on Trichomonas vaginalis. This assay was performed on some of these molecules, which revealed a relation between the structure and the position of the sulfonyl group and the antitrichomonas activity. The last part of this work describes an unexpected and original palladium-catalyzed O-arylation in fluorinated nitro(o-nitrophenyl)imidazole series involving arylboronic acids under Suzuki-Miyaura cross-coupling reaction conditions.

Presented Diploma Thesis deals with the study of electrochemical behavior of 5-nitroimidazole (5-NI), with the search for optimal conditions for its determination using techniques of DC voltammetry (DCV) and differential pulse voltammetry (DPV) at a mercury meniscus modified silver solid amalgam electrode (m-AgSAE) and at a boron-doped diamond film electrode (BDDFE), and with the comparison of reached limits of quantification (LQs). The optimal conditions found for measuring calibration dependences of 5-NI at the m-AgSAE in deionized water were as follows: Britton-Robinson buffer of pH 7.0 and 10.0 for DCV and DPV, respectively. At both thechniques, it is advisable to use an electrochemical regeneration of the electrode surface by the application of a couple of regeneration potentials Ereg,1 = 0 mV and Ereg,2 = −800 mV. The calibration dependences were measured in the concentration range from 1·10−6 to 1·10−4 mol·l−1 , with the LQs of 1.0·10−6 mol·l−1 for DCV at the m-AgSAE and 1.5·10−6 mol·l−1 for DPV at the m-AgSAE. The concentration dependences of 5-NI at the BDDFE were measured using the DCV technique in the BR buffer of pH 3.0. For the DPV technique, the optimal medium seemed to be the BR buffer of pH 2.0, however, because of the presence of an interfering peak in the supporting electrolyte,...